Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 2,937 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 2,937 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,327,670.85. Following the transaction, the executive vice president owned 23,243 shares of the company’s stock, valued at approximately $10,506,998.15. The trade was a 11.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pushkal Garg also recently made the following trade(s):

• On Friday, October 3rd, Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56.
• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $458.41, for a total value of $666,986.55.
• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Trading Down 1.0%

ALNY opened at $456.35 on Friday. The firm has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a 50-day moving average of $441.57 and a 200 day moving average of $338.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the company. Evelyn Partners Investment Management LLP lifted its position in Alnylam Pharmaceuticals by 11.5% in the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 30 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the last quarter. Bayforest Capital Ltd lifted its position in Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 39 shares during the last quarter. MAI Capital Management lifted its position in Alnylam Pharmaceuticals by 9.2% in the second quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 41 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ALNY. Piper Sandler lifted their price target on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target for the company. Bank of America boosted their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Finally, Citigroup boosted their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Twenty-four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $439.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.